CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
filed for purposes of Section 18 of the Securities Exchange Act
of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, and shall not be incorporated by
reference into any filing or other document filed by the Company
to the Exchange Act or the Securities Act of 1933, as amended
(the Securities Act), except as shall be expressly set forth by
specific reference in such filing or document. The information
provided to this Item 2.02 shall instead be deemed furnished.
authority, CTI BioPharma Corp. (the Company) issued a press
release in Italy on February 27, 2017 providing certain requested
financial information for the month ended Janaury 31, 2017 and
other information (the Monthly Italian Press Release). An English
translation of the Monthly Italian Press Release is attached as
Exhibit 99.1 and incorporated by reference herein. The financial
information contained in the Monthly Italian Press Release was
prepared at the instruction of CONSOB to Section 114, paragraph
5, of the Italian Legislative Decree no. 58/98. In communications
with CONSOB about its request that certain estimated and
unaudited financial information be disclosed by the Company, the
Company advised CONSOB that the information is not otherwise
required to be disclosed in the United States by public companies
under the U.S. securities laws. The Company further advised
CONSOB that any such financial information has not been reviewed
or audited by the Companys independent auditors as such reviews
only occur on a quarterly basis in connection with the
requirements of quarterly reports on Form 10-Q filed with the
U.S. Securities and Exchange Commission (the SEC), which reports
are prepared for the first three quarters of the year, and in
connection with the annual audit of the Companys year-end
financial statements, which is included in the Companys annual
reports on Form 10-K filed with the SEC. The Company further
advised CONSOB that any such financial information could not be
prepared in accordance with U.S. Generally Accepted Accounting
Principles (U.S. GAAP), as promulgated by the Financial
Accounting Standards Board.
Italian Press Release does not conform to U.S. GAAP because the
Company has not concluded its consideration of authoritative
literature and guidelines. Accordingly, the data presented in the
information should not be relied on for investment purposes.
Moreover, the information may deviate from values as reported in
accordance with U.S. GAAP in the Companys reviewed quarterly
financial statements and audited year-end financial statements.
Release may not be consistent with quarterly or annual financial
information presented in accordance with U.S. GAAP. This
information is being provided solely at the instruction of
CONSOB, is not used by management to evaluate the Companys
operating performance and is not presented as or intended to be
an alternative to U.S. GAAP financial information. The Company is
unable to reconcile this information to the most directly
comparable U.S. GAAP financial measures, because no such
comparable U.S. GAAP financial measures exist or are available at
the time as the Companys year-end review and audit process has
not yet been completed.
prepared in accordance with U.S. GAAP and the risk factors listed
or described from time to time in the Companys filings with the
SEC including, without limitation, the Companys filings on Forms
10-K, 10-Q, and 8-K.
filed for purposes of Section 18 of the Exchange Act or otherwise
subject to the liabilities of that section, and shall not be
incorporated by reference into any filing or other document filed
by the Company to the Exchange Act or the Securities Act except
as shall be expressly set forth by specific reference in such
filing or document. The information provided to this Item 7.01
shall instead be deemed furnished.
Press Release containing the information requested by CONSOB
discussed above. An English translation of the Monthly Italian
Press Release is attached hereto as Exhibit 99.1.
Exhibit
No.
|
Description
|
Location
|
||
99.1
|
English Translation of Press Release of CTI BioPharma
Corp., dated February 27, 2017. |
Furnished herewith.
|
About CTI BIOPHARMA CORP. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer. CTI BIOPHARMA CORP. (NASDAQ:CTIC) Recent Trading Information
CTI BIOPHARMA CORP. (NASDAQ:CTIC) closed its last trading session up +0.17 at 4.44 with 74,286 shares trading hands.